Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

WILLIAM'S HEMATOLOGY > 108: Macroglobulinemia > Flashcards

108: Macroglobulinemia Flashcards

1
Q

A lymphoid neoplasm resulting from the accumulation, in the marrow and other organs, of a clonal population of lymphocytes, lymphoplasmacytic cells, and plasma cells, which secrete a monoclonal immunoglobulin (Ig) M

A

Waldenström macroglobulinemia (WM)

WM corresponds to lymphoplasmacytic lymphoma (LPL)

Most cases of LPL are WM; less than 5% of cases can secrete IgA, IgG, κ or λ light chains, or be nonsecretory.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

TRUE OR FALSE

Lymphocytosis in WM is uncommon.

A

TRUE

Lymphocytosis in WM is uncommon.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Immunophenotypic profile of WM lymphoplasmacytic cells

A

Positive:CD19, CD20 (including FMC7), CD22, and CD79

CD5, CD10, and CD23 :10% to 20%

CD25 and CD27*

CD22dim/CD25+/CD27+/IgM+ population may be present among clonal B lymphocytes in patients with essential monoclonal gammopathy (synonym: monoclonal gammopathy of unknown significance [MGUS]) of the IgM type who ultimately saw progression to WM.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

TRUE OR FALSE

No recurrent translocations have been described in WM

A

TRUE

No recurrent translocations have been described in WM

In contrast to myeloma plasma cells, no recurrent translocations have been described in WM, which can help to distinguish WM from IgM myeloma cases, because IgM myeloma cases often exhibit t11;14 translocations.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

The most recurrent cytogenetic finding in WM cases

A

Deletions in chromosome 6q21–23

Deletions in chromosome 6q21–23: half of WM patients, with concordant gains in 6p in about 40% of 6q-deleted patients.

In a series of 174 untreated WM patients, 6q deletions, followed by trisomy 18, 13q deletions, 17p deletions, trisomy 4, and 11q deletions, were observed.

Deletion of 6q and trisomy 4 were associated with adverse prognostic markers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

The most recurrent somatic mutation in WM

A

MYD88L265P

By PCR assays, 50% to 80% of IgM MGUS patients also express MYD88L265P, and expression of this mutation was associated with increased risk for malignant progression.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

The second most common somatic mutation after MYD88L265P

A

CXCR4

Present in 30% to 35% of WM patients and impact serine phosphorylation sites that regulate CXCR4 signaling by its only known ligand, CXCL12, otherwise called stromal cell–derived factor 1a.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

The location of somatic mutations found in the C-terminus of CXCR4 in WM are similar to those observed in the germline of patients with_______ syndrome

A

WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome

A congenital immunodeficiency disorder characterized by chronic noncyclic neutropenia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

MYD88 and CXCR4 mutations

Characteristics of WM patients with MYD88L265PCXCR4NS mutations

A

Higher marrow disease involvement, serum IgM levels, symptomatic disease requiring therapy, hyperviscosity syndrome, and acquired von Willebrand disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

MYD88 and CXCR4 mutations

MYD88L265PCXCR4FS or MYD88L265PCXCR4WT

A

Intermediate marrow and serum IgM levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

MYD88 and CXCR4 mutations

MYD88WTCXCR4WT

A

Lowest marrow disease burden

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

MYD88 and CXCR4 mutation

More aggressive clinical presentation associated with what genotype

A

CXCR4NS genotype

Risk of death was not affected by CXCR4 mutation status.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

MYD88 and CXCR4 mutations

Genotype associated with risk of death and aggressive disease transformation

A

MYD88WT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

TRUE OR FALSE

In contrast to most indolent lymphomas, splenomegaly and lymphadenopathy are common

A

FALSE

In contrast to most indolent lymphomas, splenomegaly and lymphadenopathy are uncommon (≤15%).

Purpura is frequently associated with cryoglobulinemia and in rare circumstances with light-chain amyloidosis (AL)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

The morbidity associated with WM is caused by the concurrence of two main components:

A
  • Tissue infiltration by neoplastic cells
  • Physicochemical and immunologic properties of the monoclonal IgM
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Syndrome that cause marked increase in the resistance to blood flow and the resulting impaired transit through the microcirculatory system

A

Hyperviscosity Syndrome

Monoclonal IgM increases red cell aggregation and red cell internal viscosity while reducing red cell deformability.

The presence of cryoglobulins contributes to increasing blood viscosity, as well as to the tendency to induce erythrocyte aggregation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Serum viscosity is proportional to IgM concentration up to _____ g/L, then increases sharply at higher levels.

Contribute to inappropriately low erythropoietin production, which is the major reason for anemia in these patients

Renal synthesis of erythropoietin is inversely correlated with plasma viscosity.

A

30 g/L

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Hyperviscosity Syndrome

Clinical manifestations are related to circulatory disturbances that can be best appreciated by

A

Ophthalmoscopy

Shows distended and tortuous retinal veins, hemorrhages, and papilledema

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Hyperviscosity Syndrome

Symptoms usually occur when the monoclonal IgM concentration exceeds ___ g/L or when serum viscosity is greater than ____ centipoises (cp)

A

Monoclonal IgM: > 50 g/L

Serum viscosity: > 4.0 centipoises (cp)

But there is individual variability, with some patients showing no evidence of hyperviscosity even at 10 cp

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

The most common symptoms of hyperviscosity syndrome

A

Oronasal mucosal bleeding, visual disturbances because of retinal bleeding, and dizziness that rarely may lead to stupor or coma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

TRUE OR FALSE

The monoclonal IgM can behave as a cryoglobulin in up to 20% of patients and is usually type II and asymptomatic in most cases.

A

FALSE

The monoclonal IgM can behave as a cryoglobulin in up to 20% of patients and is usually type I and asymptomatic in most cases.

Mixed cryoglobulins (type II) consisting of IgM-IgG complexes may be associated with hepatitis C infections.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Treatment of cryoglobulinemia

A

Plasmapheresis or plasma exchange

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Symptoms of cryoglobulinemia

Result from impaired blood flow in small vessels

A
  • Raynaud phenomenon; acrocyanosis and necrosis of the regions most exposed to cold, such as the tip of the nose, ears, fingers, and toes;
  • Malleolar ulcers
  • Purpura
  • Cold urticaria

Renal manifestations are infrequent.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Viral infection associated with mixed cryoglobulins (type II) consisting of IgM-IgG complexes

A

Hepatitis C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

The nerve damage in Immunoglobulin M–Related Neuropathy is mediated by diverse pathogenetic mechanisms:

A
  • IgM antibody activity toward nerve constituents causing demyelinating polyneuropathies;
  • Endoneurial granulofibrillar deposits of IgM without antibody activity, associated with axonal polyneuropathy;
  • Occasionally by tubular deposits in the endoneurium associated with IgM cryoglobulin; and, rarely,
  • By amyloid deposits or by neoplastic cell infiltration of nerve structures
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Half of the patients with IgM neuropathy have a distinctive clinical syndrome that is associated with antibodies against a minor 100-kDa glycoprotein component of nerve known as

A

Myelin-associated glycoprotein (MAG)

Anti-MAG antibodies are generally monoclonal IgMκ and usually also exhibit reactivity with other glycoproteins or glycolipids that share antigenic determinants with MAG.

The anti– MAG-related neuropathy is typically distal and symmetrical, affecting both motor and sensory functions; it is slowly progressive with a long period of stability.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Immunoglobulin M–Related Neuropathy

Antiganglioside monoclonal IgMs associated with sensory ataxic neuropathy

Chronic ataxic neuropathy, sometimes with ophthalmoplegia and/or red blood cell cold-agglutinating activity

A

Anti-GD1b and anti-GQ1b antibodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Immunoglobulin M–Related Neuropathy

Associated with chronic demyelinating neuropathy and severe sensory ataxia, unresponsive to glucocorticoids

A

Monoclonal IgM proteins that bind to gangliosides with a terminal trisaccharide moiety including ganglioside M2 (GM2) and GalNac-GD1A

29
Q

Antiganglioside IgM proteins may also cross-react with lipopolysaccharides of Campylobacter jejuni, whose infection is known to precipitate the _________________, a variant of the Guillain-Barré syndrome.

A

Miller-Fisher syndrome

Molecular mimicry may play a role in this condition

30
Q

Monoclonal IgM may have cold agglutinin activity; that is, it can recognize specific red cell antigens at temperatures below ___ °C, producing chronic hemolytic anemia.

A

37 °C

temperatures below 37 °C, producing chronic hemolytic anemia.
This disorder occurs in less than 10% of WM patients

31
Q

Cold Agglutinin Hemolytic Anemia is associated with cold agglutinin titers greater than

A

1:1000

32
Q

The monoclonal component is usually an_________________ and reacts most commonly with red cell ________antigens, resulting in complement fixation and activation.

A

IgM kappa light chain (IgMκ)

I/i antigens

33
Q

Amorphous IgM deposits in the dermis result in IgM storage papules on the extensor surface of the extremities, referred to as

A

Macroglobulinemia cutis

34
Q

TRUE OR FALSE

The incidence of cardiac and pulmonary involvement is higher in patients with monoclonal IgM than with other immunoglobulin isotypes.

A

TRUE

The incidence of cardiac and pulmonary involvement is higher in patients with monoclonal IgM than with other immunoglobulin isotypes.

35
Q

The most common pulmonary symptom, followed by dyspnea and chest pain

A

Cough

36
Q

TRUE OR FALSE

In contrast to myeloma, infiltration of the kidney interstitium with lymphoplasmacytoid cells can occur in WM, and renal or perirenal masses are not uncommon.

A

TRUE

In contrast to myeloma, infiltration of the kidney interstitium with lymphoplasmacytoid cells can occur in WM, and renal or perirenal masses are NOT uncommon.

Kidney involvement is less common and less severe in WM than in myeloma

37
Q

Two cardinal features of the Schnitzler syndrome

A

Chronic urticaria and IgM gammopathy

Usually not associated initially with clinical features of WM, although evolution to WM is not uncommon

38
Q

Syndrome described as direct infiltration of the CNS by monoclonal lymphoplasmacytic cells as diffuse infiltrates or as tumors

Characterized clinically by confusion, memory loss, disorientation, seizures, and/or motor dysfunction.

A

Bing- Neel syndrome

39
Q

Most common finding in patients with symptomatic WM

A

Anemia

Caused by a combination of factors: decrease in red cell survival, impaired erythropoiesis, moderate plasma volume expansion, hepcidin production leading to an iron reutilization defect, and blood loss from the gastrointestinal tract

Usually normocytic and normochromic, and rouleaux formation is often pronounced

Mean red cell volume may be elevated spuriously owing to erythrocyte aggregation.

40
Q

Almost always present and may be the first clue to the presence of macroglobulinemia

A

Raised erythrocyte sedimentation rate

41
Q

The clotting abnormality detected most frequently

A

Prolongation of thrombin time

42
Q

Marrow finding in WM

A

Marrow infiltration by a lymphoplasmacytic cell population characterized by small lymphocytes with evidence of plasmacytoid and plasma cell maturation

The pattern of marrow infiltration may be diffuse, interstitial, or nodular, usually with an intertrabecular pattern of infiltration.

A solely paratrabecular pattern of infiltration is unusual and should raise the possibility of follicular lymphoma.

43
Q

Marrow cell immunophenotype of WM should be confirmed by flow cytometry and/or immunohistochemistry

A

sIgM+ CD19+ CD20+ CD22+ CD79+

Up to 20% of cases may express CD5, CD10, or CD23

In these cases, chronic lymphocytic leukemia and mantle cell lymphoma should be excluded.

44
Q

Characterized as “Intranuclear” periodic acid–Schiff–positive inclusions consisting of IgM deposits in the perinuclear space, and sometimes in intranuclear vacuoles

A

Dutcher-Fahey bodies

45
Q

TRUE OR FALSE

An increased number of mast cells, usually in association with the lymphoid aggregates, is commonly found in WM

A

TRUE

An increased number of mast cells, usually in association with the lymphoid aggregates, is commonly found in WM

Their presence may help in differentiating WM from other B-cell lymphomas

46
Q

Test recommended for identification and characterization of the IgM monoclonal protein

A

High-resolution electrophoresis combined with immunofixation of serum and urine

The light chain of the monoclonal IgM is κ in 75% to 80% of patients.

The concentration of the serum monoclonal protein is highly variable but, in most cases, lies within the range of 15–45 g/L.

47
Q

Used to determine IgM levels for serial evaluations

A

Densitometry

48
Q

TRUE OR FALSE

The presence of cold agglutinins or cryoglobulins may affect determination of IgM levels; therefore, testing for cold agglutinins and cryoglobulins should be performed at diagnosis.

A

TRUE

The presence of cold agglutinins or cryoglobulins may affect determination of IgM levels; therefore, testing for cold agglutinins and cryoglobulins should be performed at diagnosis.

If present, subsequent serum samples should be analyzed at 37 °C for determination of the serum monoclonal IgM level.

49
Q

Patients typically become symptomatic at serum viscosity levels of ___ cp and above, which relates to serum IgM levels above ____ g/L.

A

4 cp

60 g/L

Patients may be symptomatic at lower serum viscosity and IgM levels, and in these patients cryoglobulins may be present.

Recurring nosebleeds, headaches, and visual disturbances are common symptoms in patients with symptomatic hyperviscosity.

50
Q

Funduscopy might reveal hyperviscosity-associated findings, and among the first clinical signs of hyperviscosity:

A

Appearance of peripheral and midperipheral dot and blotlike hemorrhages in the retina

51
Q

Indications for treating WM

A
  • Patients with constitutional symptoms, such as recurrent fever, night sweats, fatigue caused by anemia, or weight loss
  • Progressive symptomatic lymphadenopathy and/or splenomegaly
  • Anemia with a hemoglobin value of 100 g/L or less or a platelet count of 100 × 109/L or less owing to marrow infiltration
  • Complications, such as hyperviscosity syndrome, symptomatic sensorimotor peripheral neuropathy, systemic amyloidosis, renal insufficiency, or symptomatic cryoglobulinemia

The panel recommended that initiation of therapy should not be based on the IgM level per se, because this may not correlate with the clinical manifestations of WM.

52
Q

Therapeuic agents for initial therapy of WM

A
  • Oral Alkylating Agents
  • Nucleoside Analogue
  • CD20-Directed Antibody
  • Proteasome Inhibitors
  • Combination Therapies
53
Q

Factors to be taken into account in considering alkylating agent therapy for patients with WM

A

Necessity for more rapid disease control given the slow response, as well as consideration for preserving stem cells in patients who are candidates for autologous SCT therapy

54
Q

Pretreatment factors associated with shorter survival in the entire population of patients receiving single-agent chlorambucil:

A
  • Age older than 60 years
  • Male sex
  • Hemoglobin less than 100 g/L
  • Leukocytes less than 4 × 109/L
  • Platelets less than 150 × 109/L
55
Q

A chimeric monoclonal antibody that targets CD20, a widely expressed antigen on lymphoplasmacytic cells in WM

A

Rituximab

4 weekly IV infusions of 375 mg/m2

56
Q

TRUE OR FALSE

In many WM patients, a permanent increase or flare of the serum IgM may occur immediately after initiation of rituximab treatment.

A

FALSE

In many WM patients, a transient increase or flare of the serum IgM may occur immediately after initiation of rituximab treatment.

Does not herald treatment failure, and most patients will return to their baseline serum IgM level by 12 weeks

57
Q

Treatment before rituximab therapy for patients with baseline serum IgM levels of greater than 50 g/L or serum viscosity of greater than 3.5 cp

A

Plasmapheresis

Because of the decreased likelihood of response in patients with higher IgM levels, as well as the possibility that serum IgM and blood viscosity levels may abruptly rise, Rituximab monotherapy should not be used as sole therapy for the treatment of patients at risk for hyperviscosity signs and symptoms.

58
Q

Patients who were treated with single-agent rituximab found the objective response rate was significantly lower in patients who had:

A

Low serum albumin (<35 g/L) or a serum monoclonal protein greater than 40 g/L

59
Q

WM patients who carried this amino acid at position 158 had a fourfold higher major response rate (ie, 50% decline in serum IgM levels) to rituximab

A

Valine

A correlation between polymorphisms at position 158 in the FcγRIIIa receptor (CD16), an activating Fc receptor on important effector cells that mediate antibody-dependent cell-mediated cytotoxicity, and rituximab response was observed in WM patients.

Individuals may encode either the amino acid valine or phenylalanine at position 158 in the FcγRIIIa receptor.

60
Q

The fully human anti-CD20 monoclonal antibody that an be used in patients with rituximab-intolerant WM.

A

Ofatumumab

61
Q

The most common grade 3 or higher adverse events with Ofatumumab

A
  • Infusion reactions (11%)
  • Chest pain (5%)
  • Hemolysis (5%)
  • Neutropenia (5%)
62
Q

Novel Therapeutics Agents for WM

A

BTK inhibitor:
Ibrutinib
Acalabrutinib
Zanubrutinib

BCL2 inhibitor: Venetoclax

63
Q

Major response rates were lower in patients with this BTKi particulkarly those with MYD88WT and CXCR4 mutations, and the National Comprehensive Cancer Network recommends genotyping before initiation

A

Ibrutinib

64
Q

Response assessments in WM rely primarily on measuring:

A

serum IgM or IgM paraprotein levels

Although complete responses require disappearance of the IgM monoclonal protein and resolution of marrow and/or extramedullary WM disease.

65
Q

The use of IgM as a surrogate marker of disease is that it can fluctuate, independent of tumor-cell killing with some agents:

Rituximab:
Bortezomib and ibrutinib:

A finding referred to as “IgM discordance”

A

Rituximab: induce a flare in serum IgM levels
Bortezomib and ibrutinib: suppress IgM levels

66
Q

TRUE OR FALSE Prognostic factors

MYD88 WT status may be an inferior prognostic marker for survival.

A

TRUE

MYD88 WT status may be an inferior prognostic marker for survival.

67
Q

TRUE OR FALSE Prognostic factors

Hemoglobin levels of less than 90–120 g/L associated with decreased survival in several series.

A

TRUE

Hemoglobin levels of less than 90–120 g/L associated with decreased survival in several series.

68
Q

International Prognostic Scoring System for WM (IPSSWM)

A
  • Advanced age (>65 years)
  • Hemoglobin less than or equal to 115 g/L
  • Platelet count less than or equal to 100 × 109/L
  • β2-microglobulin greater than 3 mg/L, and
  • Serum monoclonal protein concentration greater than 70 g/L

Importantly, the IPSSWM retained its prognostic significance in subgroups defined by age, treatment with alkylating agent, and nucleoside analogues.

WILLIAM'S HEMATOLOGY (109 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions